Cargando…
The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019
More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we...
Autores principales: | Canham, Maurice A., Campbell, John D. M., Mountford, Joanne C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503434/ https://www.ncbi.nlm.nih.gov/pubmed/32958009 http://dx.doi.org/10.1186/s12967-020-02532-4 |
Ejemplares similares
-
Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?
por: Shahani, Pradnya, et al.
Publicado: (2021) -
Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019
por: Whittaker Brown, Stacey-Ann, et al.
Publicado: (2022) -
Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment
por: Raza, Syed Shadab, et al.
Publicado: (2022) -
Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells
por: Cuesta-Gomez, Nerea, et al.
Publicado: (2021) -
Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?
por: Kirkham, Aidan M., et al.
Publicado: (2023)